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Synopsis 
Osteoporosis is a common disease characterised by reduced bone mass and increased risk of 
fracture. Genetic factors play an important role in regulating bone mass, bone turnover and bone 
geometry and also contribute to the pathogenesis of fracture by mechanisms independent of 
effects on bone density. In this article, we review the techniques that have been used to identify 
genes that regulate susceptibility to osteoporosis and discuss the major candidate genes which 
have been implicated in the regulation of bone mass and susceptibility to osteoporotic fracture. 
Introduction 
Genetic factors play an important role in the pathogenesis of osteoporosis.  The importance of 
genetic factors in regulating susceptibility to osteoporosis is highlighted by the fact that a 
positive family history of hip fracture is a strong risk factor for low bone mineral density 
(BMD) and osteoporotic fracture (1;2). Although fracture is the most important clinical 
complication of osteoporosis, most studies of genetics have focussed on BMD since this is a 
highly heritable trait (3-6) and an important clinical predictor of osteoporotic fracture risk (7). 
Nonetheless, evidence of significant genetic effects on other key determinants of osteoporotic 
fracture risk such as quantitative ultrasound properties of bone (8), femoral neck geometry (8), 
muscle strength (9), bone turnover markers (10) and body mass index (11) have also been 
reported. There is much less information on the heritability of fracture which is the most 
important clinical consequence of osteoporosis. Some investigators found little evidence to 
suggest that fractures are heritable in the elderly (12), whereas other researchers reported that 
wrist fracture had a significant genetic component with heritability estimates in the range 25%-
35% (13;14). Interestingly these studies showed that susceptibility to wrist fracture seemed to be 
largely independent of BMD. Other work has shown that the heritability of fracture is quite high 
in younger patients but falls off quite rapidly with age to almost zero in the elderly (15) which 
would explain the discrepancies between the studies cited above. Bone mineral density and the 
other traits mentioned above are regulated by multiple genes and their interaction with 
environmental factors. 
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Genetic approaches to identification of osteoporosis susceptibility genes 
Three main approaches have been implemented in the identification of genes that predispose to 
osteoporosis:  linkage analysis in pedigrees, experimental crosses in model animals and 
association studies in human populations.  The basic principle of these methods and how they 
were utilised in the identification of genetic loci for susceptibility to osteoporosis is discussed in 
more detail below. 
Linkage Analysis in Pedigrees 
Classical linkage analysis in human pedigrees has been used widely and successfully for 
mapping single-disease genes.  The principle of this approach is outlined in Figure 1, left panel.  
It involves genotyping family members for a number of polymorphic genetic markers, and then 
looking for an evidence of co-segregation of a particular marker with the disease phenotype 
under a pre-defined model of inheritance.  Genetic markers located close to the disease-causing 
gene will co-segregate with the phenotype.  Linkage is measured by lodscore and for Mendelian 
diseases is considered significant when the lodscore values exceed 3.0 (odds ratio of linkage 
against no linkage > 1000) and can be excluded when lodscore values are less than –2.0. 
Suggestive linkage is defined when lodscore values are between 2.2-3.0. For complex diseases 
where linkage studies are generally performed using non-parametric analysis methods however, 
the significance thresholds are higher and a lodscore of above 3.6 must be obtained for 
significant linkage (16).   Linkage studies are usually performed on a genome-wide basis using a 
fixed panel of microsatellite markers that are approximately 10 centimorgans apart although 
over recent years, panels of closely spaced single nucleotide polymorphism (SNP) markers have 
been developed that offer improved statistical power in performing genome wide scans for 
complex diseases (17). Genome wide scans using the classical linkage approach have been 
successfully used to map genetic loci for rare monogenic bone diseases such as osteoporosis-
pseudoglioma syndrome and high bone mass trait (18;19). However this approach is less 
suitable for the study of complex diseases such as osteoporosis or complex traits such as BMD 
because of the difficulty in finding multigenerational informative families and unknown mode 
of inheritance.  
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Another linkage analysis method for mapping quantitative trait loci (QTLs) and complex 
disease genes has been developed to tackle the limitation of the classical linkage methods. The 
analysis is based on allele sharing in sib pairs (Figure 1, middle panel). Allele sharing methods 
involve testing whether affected relatives inherit a certain chromosomal region more often than 
expected under random Mendelian segregation.  This method, in contrast to classical linkage 
studies, is not affected by locus heterogeneity and does not require construction of a disease 
model.  Therefore, allele sharing method has been the most widely used approach for mapping 
complex disease genes such as osteoporosis.  However, the success of this approach is 
dependent on the availability of a large number of sib-pairs to gain adequate statistical power to 
detect genes with modest effect.  The first genome wide linkage search to identify quantitative 
trait loci (QTLs) that contribute to the genetic variations of BMD was performed by Devoto and 
colleagues in families with history of osteoporosis (20).  The authors analysed the data using 
two different methods; the classical linkage analysis and allele sharing methods. While none of 
the QTLs identified by the classical linkage approach reached the statistical significance for 
linkage, several QTLs with suggestive or significant linkage were identified when the data were 
analysed using the allele sharing methods (Table 1) demonstrating the fact that classical linkage 
analysis is less suitable for mapping complex disease genes. 
Another statistical method to perform genome wide linkage scans was developed by Almasy 
and Blangero (21), based on variance component linkage analysis. The advantage of this 
approach is that it allows estimating the contribution of possible covariates affecting the 
phenotype under investigation. When studying BMD, the contribution of environmental factors 
(such as calcium intake, physical activity, smoking and estrogen use) as well as other important 
confounding factors such as age, weight and body mass index can be included in the variance 
component analysis.  The variance component method has been used by many investigators to 
perform genome wide scans to identify QTL that regulate BMD and other osteoporosis related 
phenotypes. Table 1 summarises the QTLs for BMD regulation identified by various genome 
wide linkage studies with significant or suggestive linkage.  
Lee and colleagues have recently performed a meta-analysis of 11 previously published 
genome-wide scans in order to assess evidence for linkage of BMD across whole genome scan 
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studies (22). They analysed the data from ~3,000 families and found that the region on 
chromosome 16pter-16p12.3 has the greatest evidence of linkage. An interesting finding to 
emerge form this meta-analysis is the identification of two chromosomal regions (10p14-q11, 
22q12-pter) with evidence for linkage that have not been detected by individual studies. 
However, the authors used published linkage scores instead of whole genome data which 
reduces the statistical power of the study and the analysis did not take into account the ethnic 
differences in genetic loci for BMD regulation.  
Genome wide scans for regulation of other osteoporosis-related phenotypes such as hip 
geometry and quantitative ultrasound properties of bone have been reported. Several loci for 
regulation of various aspects of femoral neck geometry were identified in a linkage study 
performed by Koller et al.(23). Wilson and colleagues identified two QTLs for quantitative 
ultrasound of the calcaneus on chromosome 2q33-37 and 4q12-21 in a large twin cohort (24). 
Sex-specific QTL for bone structure at the proximal femur have been also been reported (25). 
Several important observations have emerged from the linkage studies that have been performed 
in the field of osteoporosis genetics. It is now clear that most of the loci that regulate BMD do 
so in a site specific and gender specific manner although a few QTLs have been identified where 
there are effects in both genders and at BMD at more than one skeletal site. Another feature to 
emerge from studies that categorised patients by age group is that the loci regulating peak bone 
mass are probably different from those that regulating BMD in older people (26). This raises the 
possibility that genes which regulate BMD may differ from those that regulate bone loss, 
although in point of fact the evidence in favour of genetic effects on bone loss is very limited. 
Another important point is that few genome wide scans have actually identified loci that reach 
the threshold for genome wide significance and so far, only one gene for osteoporosis 
susceptibility has actually been identified so far by linkage and positional cloning and that was 
the bone morphogenetic protein 2 (BMP2)  in the isolated population of Iceland (27). 
Animal studies  
Based on the assumption that key genes regulating BMD will be shared across species, linkage 
studies in model animals provide another approach to study the genetic basis of osteoporosis.  
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The principle of this approach is outlined in Figure 1, right panel.  A cross of one inbred mouse 
strain with high BMD and another with low BMD is usually performed and followed by a 
brother-sister mating of the F1 animals to generate F2 strain of animals with varying levels of 
BMD due to segregation of the alleles that regulate BMD. A genome wide scan is performed in 
the F2 generation to identify QTLs that regulate BMD. The first genome search looking for 
QTLs for bone mass regulation in mice was performed by Klein and colleagues who identified 
10 genetic loci that were linked to bone mass in female mice and four other loci linked to body 
weight (28). Subsequent genome searches by various investigators identified many other QTLs 
for BMD regulation which are distributed across the mouse chromosomes (29-31). Gene 
mapping studies in mice have identified QTLs for other bone phenotypes of relevance to 
osteoporosis including femoral cross-sectional area (32), trabecular bone volume and 
microarchitecture (33) and mechanical properties of mouse femur (34). Interestingly, QTLs 
regulating bone phenotypes in mice were found to be gender-specific (35;36) and skeletal-site 
specific (37;38) consistent with the observations reported  in humans. Although many QTLs 
identified are specific to individual mouse strains, replication of some QTLs for BMD 
regulation has been reported between different strains suggesting that some of the genetic 
variants in these loci may be highly conserved. Furthermore, some QTLs for regulation of BMD 
identified in the mouse show synteny with QTLs identified in humans. An example is the QTL 
identified on mouse chromosome 4 near the marker D4Mit312 (Lodscore = 12.3) which is 
homologous to the QTL on the human chromosome 1p36 identified by various linkage studies 
(Table 1). Since most QTL mapping have been performed in inbred strains, fine mapping 
attempts to narrow down the QTL have been reported (39) but  so far there has been limited 
success in identifying the causative gene. A notable exception was in the case of a mouse 
chromosome 11 QTL identified by Klein and colleagues. Here the investigators studied the 
expression profile for genes within the region using microarray technology and they found that 
the expression level of Alox15 in DBA2 strain of mice (low BMD strain) was 20 fold more than 
the expression level in C57BL/6 mice (high BMD strain) suggesting that Alox15 might act as a 
negative regulator of peak bone mass in mice (40). Consistent with this hypothesis, Alox15 
knockout mice had increased BMD. A recent study has also shown that polymorphisms in the 
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human ALOX15 gene were associated with BMD in a study of postmenopausal Japanese women 
(41). The mechanism by which Alox15 regulates BMD is still unclear but it has been postulated 
that it may be involved in osteoblast and adipocyte differentiation through activation of the 
PPAR gamma receptor. A recent study has also shown that the human chromosome Xp22 
region, which is syntenic to a QTL for BMD regulation identified on mouse chromosome X, 
may also contain genes that regulate BMD in humans demonstrating the possibility of 
transferring loci for BMD regulation between the mouse and the human genomes  (42).  In 
summary, linkage studies in mice have identified many QTLs for BMD regulation but further 
studies will be required to identify the genes responsible and to investigate if these genes are 
also involved in the pathogenesis of osteoporosis in humans. 
Association studies of candidate genes 
The vast majority of information on the genes associated with osteoporosis susceptibility came 
from association studies in candidate genes. Association studies are based on comparing allele 
frequency for a polymorphism in or around a candidate gene of interest in a case and control 
group of individuals. Disease-associated alleles will be over-represented in affected individuals 
as compared with controls.  Quantitative traits such as BMD can also be investigated by 
comparing the mean values of the trait in different genotype groups for the polymorphisms 
under study. The principle of the classical association study is outlined in Figure 2. 
Recently, however, it has become possible to perform association studies on a genome wide 
basis by analyzing a large number of closely spaced single nucleotide polymorphisms (SNP) 
spread randomly across the genome (43). The rationale for these studies is that these SNPs will 
be in linkage disequilibrium with causal variants in genes that predispose to the disease under 
study. Genome wide association studies represent a major challenge in terms of statistical 
analysis, but the very might density of marker panels now available offers the prospect of 
identifying genes and genomic regions which contribute to complex diseases such as 
osteoporosis.  
The most widely studied candidate genes for BMD regulation involved those with obvious 
function in bone physiology such as the Vitamin D receptor (VDR), the collagen type I alpha 1 
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(COLIA1) and the estrogen receptor alpha gene (ESR1). Other candidate genes were studied in 
relation to osteoporosis because of their involvement in rare bone disorders affecting BMD 
regulation such as the chloride channel (CLCN7). Candidate genes located in regions of 
suggestive or significant linkage for BMD regulation identified by genome wide scans have also 
been investigated for their association with osteoporosis-related phenotypes.  The most widely 
studied candidate genes that have been implicated in the regulation of BMD and other 
osteoporosis-related phenotypes are discussed in more detail below. 
Vitamin D Receptor 
Vitamin D has important effects on bone and calcium metabolism through interaction with its 
nuclear receptor; the vitamin D receptor encoded by the VDR gene. 
The VDR was the first candidate gene to be studied in relation to osteoporosis and several VDR 
polymorphisms have now been studied in relation to BMD and other bone related phenotypes 
such as bone loss, osteocalcin levels, and osteoporotic fracture (44;45). The most widely studied 
polymorphisms are: BsmI and ApaI located in intron 8, and TaqI which is a conservative T→C 
change located in exon 9. Following the first report of an association between these 
polymorphisms and BMD by Morrison et al (44), a large number of studies were performed 
with inconsistent results. The majority of these studies have been summarised in two recent 
meta-analyses performed by Gong et al (46) and Thakkinstian et al (47). The first study 
analysed the outcome of 75 studies published between 1994 and 1998 and concluded that there 
is a significant association between VDR polymorphisms and BMD, although the effect is small 
and positive association with VDR polymorphisms were more common in studies which 
included premenopausal women rather than postmenopausal women. Furthermore, they 
suggested that the association may have been missed in some studies because of small sample 
size and the effect of other confounding factors.  Consistent with this suggestion, the 
relationship between VDR polymorphisms and BMD has been reported to be modified by 
environmental factors such as calcium and vitamin D intake (48). The second meta-analysis 
analysed studies published between 1994 and 2001 and included those which only genotyped 
the BsmI polymorphism in women (47).  The study found an evidence for lower lumbar spine 
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BMD (2.4%) in “BsmI” BB compared to Bb/bb genotypes, but no evidence for an association 
with femoral neck BMD.  Fracture has also been studied by various investigators in relation to 
the BsmI VDR polymorphism but results were inconsistent (45;49;50) . 
Functional studies performed to assess the effect of the BsmI, ApaI and TaqI polymorphisms on 
VDR function and/or gene transcription have yielded inconsistent results.  One study reported an 
evidence of haplotype-specific differences in gene transcription using reporter gene constructs 
prepared from the 3‘ region of the VDR gene (44).  Other studies have shown no differences in 
allele-specific transcription, mRNA stability, or ligand binding (51) in relation to the 
polymorphisms in the 3‘ region of the VDR gene suggesting that these polymorphisms might be 
in linkage disequilibrium with other functional polymorphisms located in the VDR gene.  
   A functional polymorphism (recognised by the FokI restriction enzyme) in exon 2 of the VDR 
gene  has been identified which introduces an alternative translational  start site resulting in a 
shorter isoform of the VDR gene (52)  Studies on the association between the FokI 
polymorphism and BMD yielded inconsistent result (52) and studies on the effect of the this  
polymorphism on the VDR function and/or transcription level were inconclusive (53). Further 
studies are required to elucidate the effects of this polymorphism.  
 Another potentially functional polymorphism has been described in the VDR promoter at a 
binding site for the transcription factor Cdx-2 and found to be associated with BMD in Japanese 
subjects (54).  It was also reported to influence DNA protein binding and to modulate gene 
expression in reporter assays (54).  
Recently, a large scale study of the VDR gene in relation to osteoporosis related phenotype has 
been reported by Fang and colleagues (55).  Participants of the Rotterdam study (n=6148) were 
genotyped for 15 haplotype-tagging SNPs selected after construction of linkage disequilibrium 
blocks across the VDR gene. The authors identified haplotype alleles in the promoter and the 
3’untranslated region (UTR) that were associated with increased risk of fracture. They observed 
48% increase in fracture risk in the subgroup of individuals (16%) who had risk genotypes at 
both regions, and this was  independent of bone mineral density. Functional analysis of VDR 
variants showed lower expression of a reporter construct with promoter risk haplotype and 
lower mRNA level of VDR expression constructs carrying 3'-UTR risk haplotype associated 
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with increased degradation of VDR mRNA. Therefore, carriers of risk haplotypes at both 
promoter and 3’UTR region have lower VDR mRNA levels attributed to the combined effect of 
decreased transcription and increased degradation of VDR mRNA. The authors suggested that 
lower VDR levels could affect the vitamin D signaling efficiency which might contribute to the 
increased fracture risk, although the mechanism by which these variants predispose to fracture is 
unclear. Since the observed increase in fracture risk associated with risk haplotypes was 
independent of BMD, a possibility of an effect on bone geometry might explain the observed 
increase in fracture risk; however, further studies will be required to confirm this hypothesis. 
Collagen type I alpha 1 
Collagen is the main structural protein of bone and is encoded by two separate genes; the 
COLIA1 gene which encodes the alpha 1 chain of type I collagen and the COLIA2 gene which 
encodes the alpha 2 chain of type 1 collagen. Both genes are important functional candidate 
genes for the genetic regulation of bone mass and osteoporosis since mutations in these genes 
account for the vast majority of osteogenesis imperfecta cases (56).  Whilst mutations affecting 
the coding region of the type I collagen genes have been excluded as a common cause of 
osteoporosis (57), attention has focused on the possibility that more subtle polymorphisms 
affecting the regulatory region of the collagen genes might predispose to osteoporosis.  Most 
attention has focused on a common polymorphism (G → T) located in intron 1 of the COLIA1 
gene which was found to alter a Sp1 transcription binding site (58). Grant and colleagues 
reported a strong association between this polymorphism and osteoporosis (58). Following this 
report, extensive studies have been performed on this polymorphism showing an association 
with BMD (58;59), and other osteoporosis-related phenotypes such as fracture risk (58;59), 
bone loss (60;61), bone geometry (62), bone mineralization (63) and bone quality(64). 
However, some studies reported no association between the COLIA1 Sp1 polymorphism and 
BMD or fracture.  Three meta-analyses of published studies investigating the Sp1 
polymorphism have been performed and concluded that the “T” allele of this polymorphism is 
associated with reduced BMD at lumbar spine and femoral neck and with increased risk of 
vertebral fractures (64-66).   Similar conclusions were reported in the large multi-centre 
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GENOMOS study (67) where the Sp1 polymorphism was genotyped in 20,786 individuals from 
several centres across Europe and significant associations with BMD and incident vertebral 
fractures were found. Interestingly, this study showed a recessive effect of the Sp1 
polymorphism on BMD contrasting with a co-dominant effect reported in previous studies, 
although the association with vertebral fracture was mediated by a co-dominant effect as 
previously reported.  
  Functional studies on the COLIA1 Sp1 polymorphism have shown evidence that the “T” allele 
is associated with increased binding affinity for Sp1 protein, three fold increase in the primary 
RNA transcripts, and increased production of type I alpha protein (64).   Furthermore, 
biomechanical testing of bone samples showed reduced bone strength and a slight reduction of 
mineralisation of bone from samples with “T” allele (63). 
   Recently, two polymorphisms (-1997G/T and -1663delT) have been described in the promoter 
of COLIA1 gene that are in linkage disequilibrium with the Sp1 polymorphism and were found 
to be associated with BMD in some (68) but not other studies (69-71).  Functional analysis 
using reporter assays showed that these polymorphisms may impact COLIA1 transcription (72). 
 More recently, a large study which included the promoter and the Sp1 polymorphism showed a 
consistent association with haplotypes which had opposing effects on both hip and spine BMD. 
These were haplotype 2 (-1997G /-1663DelT / Sp1”T”), which was significantly associated with 
low BMD and haplotype 3 (-1997T / -1663InsT / Sp1”G”) which was significantly associated 
with high BMD (Stewart et al, 2006, submitted).  These findings suggest that the association 
observed with Sp1 polymorphism previously reported by various studies may actually be driven 
by an extended haplotype spanning the promoter and intron 1 of COLIA1 gene and the 
inconsistent results reported for the Sp1 polymorphism may be attributed to differences in the 
pattern of linkage disequilibrium between different populations.  
 Estrogen receptor alpha  
In view of the fact that oestrogen deficiency following the menopause is a major risk factor for 
osteoporosis, the oestrogen receptor alpha encoded by the ESR1 gene represent an important 
candidate gene for the genetic control of osteoporosis. Three main polymorphisms of the ESR1 
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gene have been investigated; a TA repeat polymorphism in promoter region and two SNPs 
located in the first intron and defined by the restriction enzymes PvuII and XbaI.   
The TA repeat polymorphism was first reported to be associated with BMD by Sano et al (73) 
and the inton1 PvuII and XbaI polymorphisms were first shown to be associated with BMD in a 
different study of Japanese subjects (74).  Subsequently, these polymorphisms have been 
investigated in relation to BMD (74-76) and other osteoporosis related phenotypes (77;78) with 
mixed results. Ioannidis and colleagues analysed 22 studies published between 1996 and 2001 
in a meta-analysis which showed evidence for an association between XbaI polymorphism and 
both BMD and fracture (79). They found that “XX” homozygotes were associated with higher 
BMD values and reduced risk of fractures compared to other genotype groups. A more recent 
and large scale prospective meta-analysis of data from 18,917 individuals from the GENOMOS 
study showed that “XX” homozygotes were associated with reduced fracture risk confirming the 
observation from the first meta-analysis (80). However, no association with BMD was observed 
in this study suggesting that ESR1 polymorphisms might influence fracture risk by mechanisms 
that are independent of BMD such as bone quality. Consistent with this finding, a recent study 
have shown a significant association of ESR1 polymorphisms with ultrasound properties of bone 
and rates of postmenopausal bone loss in a large cohort of ~3000 women (81). 
The data assembled so far indicate that allelic variation at the ESR1 gene contributes to the 
genetic regulation of osteoporosis. Although there is an evidence from reporter gene assays to 
suggest that the PvuII polymorphism creates a functional binding site for the transcription factor 
B-Myb (82), the impact of this polymorphism on ESR1 transcription has not been determined 
and further studies are required to elucidate the mechanisms by which ESR1 alleles regulate 
bone-phenotypes. 
Transforming Growth Factor beta 1 
The TGFβ1 gene has been extensively studied as a potential regulator of susceptibility to 
osteoporosis partly because it is particularly abundant in bone and has been shown to have 
effects on both osteoblast and osteoclast function in vitro (83). One of the earliest studies was 
that of Langdahl and colleagues who identified a polymorphism within intron 4 of the TGFβ1 
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that was associated with severe osteoporosis (84). Subsequent work by the same group 
evaluated the relationship between several polymorphisms in TGFβ1 and osteoporosis in a case 
control study and identified an association between a polymorphism located in the fifth intron 
and BMD (85).  Other research has focused on polymorphisms in the promoter and first exon of 
TGFβ1 in relation to BMD (86-88). A protein coding polymorphism causing a leucine to proline 
substitution in the signal peptide region of TGFβ1 has been found to be associated with BMD 
and with circulating TGFβ1 in some populations (86;88), although the mechanisms by which 
this polymorphism regulates BMD is unclear. There have been many studies of TGFβ1 alleles 
in relation to BMD and other osteoporosis genotypes but most have been of limited sample size 
and as a consequence of this, somewhat conflicting results have been reported. Definitive 
evidence that genetic variation in TGFβ1 can regulate bone mass in humans comes from the 
observation that Camurati-Engelmann disease (a rare bone dysplasia characterized by 
osteosclerosis affecting the diaphysis of long bones) is caused by mutations in TGFβ1 (89;90). 
These mutations activate TGFβ1 signaling by inhibiting binding of the mature TGFβ1 peptide 
to the inhibitory latency associated peptide (91).  
Lipoprotein Receptor Related protein 5 (LRP5) 
Various mutations in the LRP5 gene were recently found to be responsible for two rare bone 
disorders; osteoporosis-pseudoglioma syndrome (OPS, a disorder characterised by juvenile 
onset osteoporosis  and visual loss) and autosomal dominant inheritance of high bone mass 
(HBM) (92-94). Inactivating mutations of LRP5 are responsible for OPS, whereas gain-of 
function mutations are responsible for the HBM syndrome. The LRP5 gene encodes a 
transmembrane receptor, which is involved in Wnt signaling (94) and several polymorphisms of 
the LRP5 gene have now been investigated in relation to BMD.  Ferrari and colleagues analysed 
several polymorphisms of the LRP5 gene in relation to BMD and identified significant 
association between G2047A polymorphism and lumbar spine BMD, but the association was 
most significant in men (95). However, subsequent studies have reported association between 
BMD and various haplotypes defined by polymorphisms in the LRP5 in both men and women 
(96;97). 
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Current evidence suggest that LRP5 pathway regulates bone mass mainly by affecting bone 
formation, reflected by the fact that individuals with activating mutations have increased 
biochemical markers of bone formation, but no disturbance in bone resorption (94). Consistent 
with this suggestion, heterozygous LRP5 knockout mice have decreased trabecular bone volume 
density (98) and mice with high bone mass LRP5 G171V mutation have increased bone cross-
sectional area and thickness (99).  . Functional analysis of the high bone mass associated 
mutations of LRP5 has shown that they probably cause activation of beta-catenin signaling by 
inhibiting interactions between LRP5 and the inhibitor of Wnt signalling Dkk1. An initial study 
by Boyden and colleagues (94) showed that the G171V mutation did not result in constitutive 
activation of LRP5 signaling in vitro but that it impaired Dkk1 mediated inhibition of Wnt 
stimulated LRP5 signaling. Another study reached the same conclusion in showing that several 
HBM-associated mutants (G171V, G171R, A214T, A214V, A242T, T253I and D111Y) were 
resistant to Dkk1 inhibition compared with wild type LRP5 and had lower affinity for Dkk1 
binding (100). Although the mechanisms by which rare LRP5 mutations affect bone turnover 
seems reasonably well worked out, further studies will be required to define the mechanism by 
which the more subtle polymorphisms in LRP5 affect bone mass. 
Core-Binding Factor A 1 (CBFA1) 
The CBFA1 gene (also known as RUNX2) plays an essential role in regulating osteoblast 
differentiation since mice which are deficient in this transcription factor have complete absence 
of bone (101;102), whereas mice with haploinsufficiency of CBFA1 phenocopy the human 
syndrome of cleidocranial dysplasia (CCD), a skeletal disorder characterized by short stature, 
hypoplasia or aplasia of the clavicles, patent fontanelles, supernumerary teeth and other defects 
in skeletal patterning and growth (102).  The human syndrome of CCD is caused by various 
missense, nonsense and frameshift mutations of CBFA1 (103). Various polymorphisms have 
been identified in CBFA1 and some of these have been associated with bone mass in population 
based studies (104-106). The best functional candidate polymorphism lie within the CBFA1 
promoter or within polyalanine and polyglutamine repeats in exon 1 (104). The polyalanine and 
polyglutamine repeats are of special interest since they lie within one of the transactivation 
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domains of CBFA1. Various polymorphic variations have been identified in this region 
including a 18bp deletion which results in a polyalanine repeat of 11 residues (11 ala) compared 
with the more common repeat of 17 residues (17 ala). Various rare length variants within the 
polyglutamine repeat have also been identified resulting in stretches of between 15 and 30 
repeats.  The strongest association with BMD has been observed with an anonymous 
polymorphism in the Ala repeat region (105;106), although it is thought that this might be due to 
linkage disequilibrium with polymorphisms in the promoter which have been shown to affect 
CBFA1 transcription in reporter assays (104). It is currently unclear whether the length variants 
in the polyalanine and polyglutamine tracts have functional importance, but this is an area of 
ongoing investigation. 
Tumor Necrosis Factor Receptor Superfamily 1B (TNFRSF1B) 
The TNFRSF1B (also known as TNFR2) mediates the effects of TNF which have an important 
role in regulating bone turnover. Specifically, TNF-α induced activation of the TNFRSF1B 
receptor has been found to suppress osteoclastogenesis in vitro, contrasting with its effects on 
the TNFRSF1A receptor which results in enhanced osteoclastogenesis  (107). The TNFRSF1B 
gene is located on chromosome 1p36 region which was found to be linked to BMD in three 
independent studies, rendering it both a positional and functional candidate for the regulation of 
BMD (20;108;109). Polymorphisms in the 3’UTR of TNFRSF1B have been reported to be 
associated with spine BMD in a small population based study of American population (110). 
However, a larger study in Scottish women showed an association with femoral neck but not 
lumbar spine BMD (111) consistent with the linkage findings identified by genome wide 
linkage scan (20). Since these polymorphisms are located in the 3’UTR, it has been postulated 
that these polymorphisms might influence TNFRSF1B mRNA level by affecting the mRNA 
structure and stability. 
CLCN7 and TCIRG1 
 
Mutations in genes encoding chloride channel 7 (CLCN7) and osteoclast specific proton pump 
(TCIRG1) have been found to cause some forms of osteopetrosis (112), a disease characterised 
by increased BMD due to impaired osteoclast function. Both genes are highly expressed in 
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osteoclast and play a significant role in acidification of the lacunae during bone resorption. 
Polymorphisms in the CLCN7 and TCIRG1 have been reported to be associated with BMD 
(113;114), however, further studies in different population will be required to confirm these 
findings. 
 
Other candidate genes 
Polymorphisms of many other candidate genes have been studied in relation to BMD and other 
osteoporosis-related genotypes (reviewed by Liu et al (115)).  Constraints of space limit full 
discussion of these genes, which in general have been investigated in populations with a limited 
sample size. Further studies will be required to confirm their candidacy as genetic regulators of 
bone mass. 
Conclusion 
Many advances have been made in understanding the mechanisms by which genetic factors 
regulate susceptibility to osteoporosis over the past 10 years. It has become clear from studies in 
man and experimental animals that different genes regulate BMD at different skeletal sites and 
in men and women. Linkage studies have identified several chromosomal regions that regulate 
BMD but only a few causative genes have been discovered so far using this approach. In 
contrast, significant advances have been made in identifying the genes that cause monogenic 
bone diseases and polymorphic variation in some of these genes has been found to contribute to 
the genetic regulation of BMD in the normal population. Other genes which have been 
investigated as possible candidates for susceptibility to osteoporosis such as vitamin D because 
of their role in bone biology have yielded mixed results. Many candidate gene association 
studies have been underpowered and meta-analysis has been used to try to confirm or refute 
potential association and gain a better estimate of their true effect size in the population. Most of 
the genetic variants which confer susceptibility to osteoporosis remain to be discovered and it is 
likely that new techniques such as whole –genome association will provide new insights into the 
genetic determinants of osteoporosis and will help to identify genes of modest effect size. From 
a clinical standpoint, genetic variants that are found to predispose to osteoporosis will advance 
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our understanding of the pathophysiology of the disease and could be developed as diagnostic 
genetic tests or form molecular target for design of new drugs for the prevention and treatment 
of osteoporosis and other bone diseases.  
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Figure 1. Genetic approaches used in the identification of osteoporosis susceptibility genes. 
Classical linkage analysis Allele-sharing in sib-pairs Linkage analysis in animal models  
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disease genes when mode of inheritance can not be 
defined. 
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strains of animals. In the above example a mouse 
strain with low BMD is crossed with a high BMD 
strain and genetic loci can be identified by analysis of 
F2 generation looking for co-segregation of genetic 
markers with BMD loci. 
Advantage: large number of animals can be 
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under investigation.  
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Table 1. Major quantitative trait loci for BMD identified by linkage analysis in humans 
Study  Study Design  Statistical approach Chromosom
e 
Lod 
score  
Phenotype Gender 
Devoto et al (1998) (20)
  
History of osteoporosis  Allele-sharing 1p36 2.29 FN-BMD M&F 
   2p23-24 2.25 LS-BMD M&F 
   4qter 2.28 FN-BMD M&F 
Niu et al (1999) (116) Healthy sib-pair Allele-sharing 2p21-24 2.15 Forearm-BMD M&F 
Koller et al (2000) (117) Healthy sib-pair Allele-sharing 1q21-23 3.11 LS-BMD F 
Karasik et al (2002) 
(118) 
Normal Population Variance component 21q22.2 2.39 TR-BMD M&F 
   21qter 3.14 TR-BMD M&F 
Deng et al (2002) (119) Proband with low BMD Variance component 4q31-32 3.08 Spine BMD M&F 
   10q26 2.29 FN- BMD M&F 
   13q33-34 2.43 LS- BMD M&F 
Karasik et al (2003) 
(120) 
Normal Population Variance component 9q22-31 2.71 FN-BMD F 
   12q23-24 3.00 TR-BMD F 
   14q31 2.48 LS-BMD F 
Kammerer et al (2003) 
(121) 
Normal Population Variance component 2p25 3.98 FN-BMD M 
   4p15 4.33 Forearm BMD M & F 
   6q27 2.27 TR-BMD M & F 
   12q24 2.24 Forearm BMD M & F 
   13q14 3.46 TR-BMD M 
   13q14 2.51 FN-BMD M 
Wilson et al (2003) (109) Dizygotic female twins Allele sharing 1p36 2.38 Whole body 
BMD 
F 
   3p21 2.72 LS-BMD F 
Styrkarsdottir et al 
(2003)(27) 
History of osteoporosis Allele-sharing 20p12 3.18 FN-BMD M & F 
   20p12 2.89 LS-BMD M & F 
Shen et al (2004) (122) Normal population + 
probands with low 
BMD 
Variance component 11q23 3.13 LS-BMD M & F 
   Xq27 4.30 Forearm BMD M & F 
   Xq27 2.57 FN-BMD M & F 
Ralston et al (2005) (26) History of osteoporosis Variance component 3q25 2.43 FN-BMD M 
   4q25 2.22 FN-BMD M 
   4q25 2.55 FN-BMD F 
   7p14 2.28 FN-BMD M 
   10q21 4.2 FN-BMD M 
   16p13 2.52 FN-BMD M 
   16q23 2.28 LS-BMD F 
   18p11 2.83 LS-BMD F 
   20q13 3.2 LS-BMD F 
Peacock et al (2005) 
(123) 
Normal population Allele sharing 1q 3.13 LS-BMD M 
   2p 4.4 LS-BMD M & F 
   2q 2.99 FN-BMD M 
   14p 4.6 LS-BMD M 
Abbreviations: FN= femoral neck, LS= Lumbar spine, TR=trochanter, BMD= bone mineral density, 
M=Males, F= Females 
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Figure 2. Using association studies to identify genes for BMD regulation. 
Association studies in candidate genes 
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Positive association can arise due to the following reasons: 
• True association when the associated polymorphism contributes to the phenotype  
• The associated polymorphism is in linkage disequilibrium with actual cause of the disease, 
which can be another polymorphism in the same gene or in a gene nearby. 
• False association due to population stratification when the population contains subgroups with 
varying allele frequencies for that polymorphism. 
Interpretation of results 
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